Logo

BridgeBio Entered into an Asset Purchase Agreement with Sentynl to Commercilize Nulibry (fosdenopterin) for Molybdenum Cofactor Deficiency

Share this
BridgeBio Entered into an Asset Purchase Agreement with Sentynl to Commercilize Nulibry (fosdenopterin) for Molybdenum Cofactor Deficiency

BridgeBio Entered into an Asset Purchase Agreement with Sentynl to Commercilize Nulibry (fosdenopterin) for Molybdenum Cofactor Deficiency

Shots:

  • BridgeBio to receive cash payments upon the achievement of regulatory milestones & will be eligible to receive commercial milestones along with royalties on sales of Nulibry
  • Sentynl to acquire global rights to Nulibry & will be responsible for the ongoing development & commercialization of Nulibry in the US along with fosdenopterin globally
  • BridgeBio will be responsible to share the development responsibilities for fosdenopterin through approval of the MAA & regulatory submission with the Israeli Ministry of Health. Nulibry has been approved in the US to reduce the risk of mortality in patients with MoCD Type A & studies showed an improvement in OS over the historical control group

Ref: Globe Newswire | Image: BridgeBio

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions